Medicine:舒芬太尼辅助罗哌卡因用于剖宫产术缓解硬膜外麻醉下瘢痕宫产 妇躯体内脏疼痛的剂量效应

2018-10-30 何幼芹 罂粟花 微信号

舒芬太尼和罗哌卡因联合运⽤可缓解瘢痕⼦宫产妇在硬膜外麻醉下⾏剖宫产术过程中的躯体内脏疼痛,当舒芬太尼的剂量在15 μg -20 μg 之间时可使患者的满意度最⼤化。

背景与目的

在剖宫产期间产妇使用小剂量局部麻醉剂进行硬膜外麻醉时,内脏性疼痛的发生很常见。为了减少或避免因腹腔脏器牵拉产生这种并发症,本实验旨在探究瘢痕子宫产妇在硬膜外麻醉下行剖宫产时舒芬太尼作为局部麻醉剂的辅助用药对于缓解内脏性疼痛的50%和95%有效剂量。

方  法

在这项随机,双盲, 剂 量范围研究中共纳?100例在硬膜外麻醉下选择期剖宫产的瘢痕子宫产妇。各实验组分别为5、10、15、20及25 μg 的舒芬太尼作为10ml 0.65%罗哌卡因的辅助?药。将成功的硬膜外麻醉定义为在硬膜外给药后20min内感觉阻滞平达到第六胸椎(T6)和/或在剖宫产期间未发生因腹腔脏器牵拉诱发的疼痛。利用逻辑回归模型估算ED50和ED90。

结  果

未发现内脏疼痛 患者 的硬膜外舒芬太尼的ED50和ED90分别为10.7 μg (95%CI:2.4-14.4 μg )和28.1 μg (95%CI:19.4-44.0 μg )。感觉阻滞的起效时间,最大Bromage分级和运动阻滞的持续时间在舒芬太尼>20 μg 时存在显着的差别(p<0.05,与其他的剂量组较)。然而,硬膜外舒芬太尼>20 μg 会增加不良反应的发生率。与其他不同剂量的舒芬太尼相比,硬膜外注射15 μg -20 μg 舒芬太尼可使患者的满意度得到极大的提高。

结  论

研究结果表明,舒芬太尼和罗哌卡因联合运用可缓解瘢痕子宫产妇在硬膜外麻醉下?剖宫产术过程中的躯体内脏疼痛,当舒芬太尼的剂量在15 μg -20 μg 之间时可使患者的满意度最大化。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1773738, encodeId=4d371e73738f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 19 04:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858905, encodeId=a3e018589054c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Aug 13 14:21:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688946, encodeId=da261688946a6, content=<a href='/topic/show?id=ad6186604b7' target=_blank style='color:#2F92EE;'>#舒芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86604, encryptionId=ad6186604b7, topicName=舒芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2e28689439, createdName=12498b37m81暂无昵称, createdTime=Sun Mar 10 12:21:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027260, encodeId=d900202e260c2, content=<a href='/topic/show?id=5259e36453f' target=_blank style='color:#2F92EE;'>#硬膜外麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73645, encryptionId=5259e36453f, topicName=硬膜外麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Thu Sep 26 06:21:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937151, encodeId=53e9193e15187, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 21 15:21:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336972, encodeId=290b13369e2be, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384827, encodeId=6e5b138482e2e, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512570, encodeId=954f15125e0ab, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577629, encodeId=4ba215e7629a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609261, encodeId=f174160926148, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2019-08-19 kalseyzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1773738, encodeId=4d371e73738f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 19 04:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858905, encodeId=a3e018589054c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Aug 13 14:21:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688946, encodeId=da261688946a6, content=<a href='/topic/show?id=ad6186604b7' target=_blank style='color:#2F92EE;'>#舒芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86604, encryptionId=ad6186604b7, topicName=舒芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2e28689439, createdName=12498b37m81暂无昵称, createdTime=Sun Mar 10 12:21:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027260, encodeId=d900202e260c2, content=<a href='/topic/show?id=5259e36453f' target=_blank style='color:#2F92EE;'>#硬膜外麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73645, encryptionId=5259e36453f, topicName=硬膜外麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Thu Sep 26 06:21:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937151, encodeId=53e9193e15187, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 21 15:21:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336972, encodeId=290b13369e2be, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384827, encodeId=6e5b138482e2e, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512570, encodeId=954f15125e0ab, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577629, encodeId=4ba215e7629a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609261, encodeId=f174160926148, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2019-08-13 jeanqiuqiu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1773738, encodeId=4d371e73738f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 19 04:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858905, encodeId=a3e018589054c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Aug 13 14:21:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688946, encodeId=da261688946a6, content=<a href='/topic/show?id=ad6186604b7' target=_blank style='color:#2F92EE;'>#舒芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86604, encryptionId=ad6186604b7, topicName=舒芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2e28689439, createdName=12498b37m81暂无昵称, createdTime=Sun Mar 10 12:21:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027260, encodeId=d900202e260c2, content=<a href='/topic/show?id=5259e36453f' target=_blank style='color:#2F92EE;'>#硬膜外麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73645, encryptionId=5259e36453f, topicName=硬膜外麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Thu Sep 26 06:21:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937151, encodeId=53e9193e15187, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 21 15:21:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336972, encodeId=290b13369e2be, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384827, encodeId=6e5b138482e2e, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512570, encodeId=954f15125e0ab, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577629, encodeId=4ba215e7629a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609261, encodeId=f174160926148, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1773738, encodeId=4d371e73738f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 19 04:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858905, encodeId=a3e018589054c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Aug 13 14:21:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688946, encodeId=da261688946a6, content=<a href='/topic/show?id=ad6186604b7' target=_blank style='color:#2F92EE;'>#舒芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86604, encryptionId=ad6186604b7, topicName=舒芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2e28689439, createdName=12498b37m81暂无昵称, createdTime=Sun Mar 10 12:21:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027260, encodeId=d900202e260c2, content=<a href='/topic/show?id=5259e36453f' target=_blank style='color:#2F92EE;'>#硬膜外麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73645, encryptionId=5259e36453f, topicName=硬膜外麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Thu Sep 26 06:21:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937151, encodeId=53e9193e15187, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 21 15:21:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336972, encodeId=290b13369e2be, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384827, encodeId=6e5b138482e2e, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512570, encodeId=954f15125e0ab, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577629, encodeId=4ba215e7629a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609261, encodeId=f174160926148, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1773738, encodeId=4d371e73738f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 19 04:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858905, encodeId=a3e018589054c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Aug 13 14:21:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688946, encodeId=da261688946a6, content=<a href='/topic/show?id=ad6186604b7' target=_blank style='color:#2F92EE;'>#舒芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86604, encryptionId=ad6186604b7, topicName=舒芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2e28689439, createdName=12498b37m81暂无昵称, createdTime=Sun Mar 10 12:21:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027260, encodeId=d900202e260c2, content=<a href='/topic/show?id=5259e36453f' target=_blank style='color:#2F92EE;'>#硬膜外麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73645, encryptionId=5259e36453f, topicName=硬膜外麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Thu Sep 26 06:21:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937151, encodeId=53e9193e15187, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 21 15:21:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336972, encodeId=290b13369e2be, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384827, encodeId=6e5b138482e2e, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512570, encodeId=954f15125e0ab, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577629, encodeId=4ba215e7629a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609261, encodeId=f174160926148, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1773738, encodeId=4d371e73738f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 19 04:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858905, encodeId=a3e018589054c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Aug 13 14:21:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688946, encodeId=da261688946a6, content=<a href='/topic/show?id=ad6186604b7' target=_blank style='color:#2F92EE;'>#舒芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86604, encryptionId=ad6186604b7, topicName=舒芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2e28689439, createdName=12498b37m81暂无昵称, createdTime=Sun Mar 10 12:21:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027260, encodeId=d900202e260c2, content=<a href='/topic/show?id=5259e36453f' target=_blank style='color:#2F92EE;'>#硬膜外麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73645, encryptionId=5259e36453f, topicName=硬膜外麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Thu Sep 26 06:21:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937151, encodeId=53e9193e15187, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 21 15:21:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336972, encodeId=290b13369e2be, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384827, encodeId=6e5b138482e2e, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512570, encodeId=954f15125e0ab, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577629, encodeId=4ba215e7629a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609261, encodeId=f174160926148, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1773738, encodeId=4d371e73738f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 19 04:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858905, encodeId=a3e018589054c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Aug 13 14:21:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688946, encodeId=da261688946a6, content=<a href='/topic/show?id=ad6186604b7' target=_blank style='color:#2F92EE;'>#舒芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86604, encryptionId=ad6186604b7, topicName=舒芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2e28689439, createdName=12498b37m81暂无昵称, createdTime=Sun Mar 10 12:21:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027260, encodeId=d900202e260c2, content=<a href='/topic/show?id=5259e36453f' target=_blank style='color:#2F92EE;'>#硬膜外麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73645, encryptionId=5259e36453f, topicName=硬膜外麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Thu Sep 26 06:21:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937151, encodeId=53e9193e15187, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 21 15:21:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336972, encodeId=290b13369e2be, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384827, encodeId=6e5b138482e2e, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512570, encodeId=954f15125e0ab, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577629, encodeId=4ba215e7629a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609261, encodeId=f174160926148, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2018-11-01 xue8602
  8. [GetPortalCommentsPageByObjectIdResponse(id=1773738, encodeId=4d371e73738f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 19 04:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858905, encodeId=a3e018589054c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Aug 13 14:21:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688946, encodeId=da261688946a6, content=<a href='/topic/show?id=ad6186604b7' target=_blank style='color:#2F92EE;'>#舒芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86604, encryptionId=ad6186604b7, topicName=舒芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2e28689439, createdName=12498b37m81暂无昵称, createdTime=Sun Mar 10 12:21:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027260, encodeId=d900202e260c2, content=<a href='/topic/show?id=5259e36453f' target=_blank style='color:#2F92EE;'>#硬膜外麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73645, encryptionId=5259e36453f, topicName=硬膜外麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Thu Sep 26 06:21:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937151, encodeId=53e9193e15187, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 21 15:21:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336972, encodeId=290b13369e2be, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384827, encodeId=6e5b138482e2e, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512570, encodeId=954f15125e0ab, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577629, encodeId=4ba215e7629a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609261, encodeId=f174160926148, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1773738, encodeId=4d371e73738f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 19 04:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858905, encodeId=a3e018589054c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Aug 13 14:21:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688946, encodeId=da261688946a6, content=<a href='/topic/show?id=ad6186604b7' target=_blank style='color:#2F92EE;'>#舒芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86604, encryptionId=ad6186604b7, topicName=舒芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2e28689439, createdName=12498b37m81暂无昵称, createdTime=Sun Mar 10 12:21:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027260, encodeId=d900202e260c2, content=<a href='/topic/show?id=5259e36453f' target=_blank style='color:#2F92EE;'>#硬膜外麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73645, encryptionId=5259e36453f, topicName=硬膜外麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Thu Sep 26 06:21:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937151, encodeId=53e9193e15187, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 21 15:21:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336972, encodeId=290b13369e2be, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384827, encodeId=6e5b138482e2e, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512570, encodeId=954f15125e0ab, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577629, encodeId=4ba215e7629a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609261, encodeId=f174160926148, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1773738, encodeId=4d371e73738f6, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 19 04:21:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1858905, encodeId=a3e018589054c, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Tue Aug 13 14:21:00 CST 2019, time=2019-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688946, encodeId=da261688946a6, content=<a href='/topic/show?id=ad6186604b7' target=_blank style='color:#2F92EE;'>#舒芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86604, encryptionId=ad6186604b7, topicName=舒芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9f2e28689439, createdName=12498b37m81暂无昵称, createdTime=Sun Mar 10 12:21:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2027260, encodeId=d900202e260c2, content=<a href='/topic/show?id=5259e36453f' target=_blank style='color:#2F92EE;'>#硬膜外麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73645, encryptionId=5259e36453f, topicName=硬膜外麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Thu Sep 26 06:21:00 CST 2019, time=2019-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1937151, encodeId=53e9193e15187, content=<a href='/topic/show?id=c06ae363256' target=_blank style='color:#2F92EE;'>#硬膜外#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73632, encryptionId=c06ae363256, topicName=硬膜外)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Fri Jun 21 15:21:00 CST 2019, time=2019-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336972, encodeId=290b13369e2be, content=<a href='/topic/show?id=48f8e12220f' target=_blank style='color:#2F92EE;'>#瘢痕#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71222, encryptionId=48f8e12220f, topicName=瘢痕)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fa82500120, createdName=12498a1cm67暂无昵称, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384827, encodeId=6e5b138482e2e, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512570, encodeId=954f15125e0ab, content=<a href='/topic/show?id=c964e959555' target=_blank style='color:#2F92EE;'>#罗哌卡因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79595, encryptionId=c964e959555, topicName=罗哌卡因)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e2a10479591, createdName=ms6832696159214430, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577629, encodeId=4ba215e7629a1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609261, encodeId=f174160926148, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Nov 01 09:21:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]

相关资讯

Sci Rep:右美托咪啶联合舒芬太尼静脉自控镇痛可减轻剖宫产产妇术后疼痛:前瞻性、随机对照、多中心研究

本研究旨在评价右美托咪啶用于剖宫产术后患者静脉自控镇痛(PCA)的有效性和安全性。

J Int Med Res:纳布啡和舒芬太尼用于结肠镜检查的比较:一项随机对照试验

纳布啡作为围术期镇痛药其疗效与吗啡相当,但其疗效并未在临床试验中直接与舒芬太尼比较。本研究的目的是比较纳布啡和舒芬太尼在肠镜患者中的疗效和安全性,以及确定此适应症中纳布啡的最佳剂量。

Anaesthesia:舒芬太尼对老年患者脑电双频指数的影响

本研究的目的是评估异丙酚麻醉诱导过程中加入舒芬太尼对老年患者(≥65岁)脑电双频指数的影响。